Brief: Opgen’S Subsidiary Curetis Meets All Remaining Key Milestones In Research And Development Collaboration With Find
26/04/2023 23:21
April 26 (Reuters) - OpGen Inc OPGN.O :
* OPGEN’S SUBSIDIARY CURETIS MEETS ALL REMAINING KEY
MILESTONES IN
RESEARCH AND DEVELOPMENT COLLABORATION WITH FIND
* OPGEN - CO'S GERMAN SUBSIDIARY CURETIS GMBH HAS MET
REMAINING
KEY MILESTONES UNDER INITIAL RESEARCH AND DEVELOPMENT
COLLABORATION AGREEMENT WITH FIND
Source text for Eikon: ID:nGNXbDgkNq
Further company coverage: OPGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CapForce
See all newsBrief: Opgen Says Financial Statements Contained Within Quarterly Report On Form 10-Q For Q1 2024 Should No Longer Be Relied Upon
Brief: Opgen Inc - Received Nasdaq Notice That Co Is Not In Compliance With Minimum Stockholders' Equity Requirement For Continued Listing
Brief: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
Brief: OpGen Announces 1-For-10 Reverse Stock Split
Brief: David E. Lazar Reports 19.9% Stake In Opgen Inc As Of March 25- SEC Filing